Generation of Neutralizing Anti-B19 Parvovirus Human Monoclonal Antibodies from Patients Infected with Human Immunodeficiency Virus

Susan Zolla-Pazner, Serguei Arakelov, Miroslaw K. Gorny, Constance Williams, Charles H. Riggin, Francine Brady, Marc S. Collett, Serguei Arakelov, Miroslaw K. Gorny, Constance Williams, Charles H. Riggin, Francine Brady, Marc S. Collett

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

The prevalence of IgG antibodies to human B19 parvovirus (anti-BI9) is elevated in individuals infected with human immunodeficiency virus (HIV), especially during the later stages of HIV infection. In subjects with high titers of IgG anti-B19, 86% (19 of 22) had circulating B cells producing anti-BI9. Immortalization of these cells with Epstein-Barr virus and generation of heterohybridomas by fusion with a mouse × human heteromyeloma resulted in the production of two cell lines producing IgG1κ monoclonal antibodies (MAbs). Both ofthese MAbs were specific for conformational epitopes on the VP2 capsid protein of B19 parvovirus and both were capable of neutralizing 50% of the viral infectivity in a human erythroid colony-forming unit assay at ⩽ 1 εg of MAb/mL. These human MAbs are potentially useful in the treatment of acute B19 parvovirus infection.

Original languageEnglish
Pages (from-to)580-585
Number of pages6
JournalJournal of Infectious Diseases
Volume168
Issue number3
DOIs
StatePublished - 1 Jan 1993
Externally publishedYes

Fingerprint

Dive into the research topics of 'Generation of Neutralizing Anti-B19 Parvovirus Human Monoclonal Antibodies from Patients Infected with Human Immunodeficiency Virus'. Together they form a unique fingerprint.

Cite this